Colorectal cancer
Conditions
Interventions
None listed
Sponsors
Sysmex corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Patients with pathologically confirmed primary colorectal adenocarcinoma -Patients who are planned to be tested or already tested for BRAF testing using the MEBGEN RASKET-B kit as part of routine clinical practice, and the tissue sample is free of modifying radiation therapy or drug therapy -Patients aged 18 or older at the time of consent acquisition -Patients whose blood sample can be collected before surgery or initiation of drug therapy -Patients diagnosed with Stage IV or recurrent colorectal cancer by imaging findings -Patients with no prior drug therapy, or patients confirmed progressive disease (PD) based on imaging or clinical PD during drug therapy without having initiated subsequent treatment -Patient's written consent to participate in this study has been obtained
Exclusion criteria
Exclusion criteria: -Patients judged ineligible to participate in the study -Patients previously enrolled in this study -Patients with history of multiple cancer or with a comorbid multiple cancer -Patients with synchronous or metachronous (within 5 years of disease-free interval) double cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity and specificity of Test method compared to Reference method for the detection of BRAF V600E mutation. | — |
Secondary
| Measure | Time frame |
|---|---|
| -Diagnostic accuracy of Test method compared to Reference method. -Positive predictive value (PPV) and negative predictive value (NPV) of Test method compared to Reference method. | — |
Countries
Japan
Contacts
Public ContactMasahiro Nishida
Sysmex Corporation Medical & Scientific Affairs
Outcome results
None listed